Clinical Trial Update: A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 study of NP001 in amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• NP001

Snippet

Sponsor: Neuraltus Pharmaceuticals, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED